PMID- 37152882
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20231031
IS  - 1841-0987 (Print)
IS  - 1843-066X (Electronic)
IS  - 1841-0987 (Linking)
VI  - 18
IP  - 4
DP  - 2022 Oct-Dec
TI  - A non-invasive method for estimating the severity of liver steatosis and the risk 
      of fibrosis in non-obese type 2 diabetes patients with NAFLD.
PG  - 480-487
LID - 10.4183/aeb.2022.480 [doi]
AB  - CONTEXT: Prognostic considerations include assessing the risk of liver fibrosis 
      in people with non-alcoholic fatty liver disease (NAFLD). OBJECTIVES: This study 
      evaluates the use of hematologic and metabolic parameters regarding liver 
      steatosis and fibrosis scores (FLI and Fib-4) in non-obese type 2 diabetes 
      mellitus (t2DM) patients with NAFLD. METHODS: Subjects underwent abdominal 
      ultrasound examinations, and FLI and Fib-4 scores were calculated to evaluate 
      liver steatosis and the risk of liver fibrosis non-invasively: 61 non-obese NAFLD 
      subjects with t2DM were included in the cohort study and were divided into 2 
      groups depending on the t2DM treatment regimen. RESULTS: Fib-4 and WBC count 
      demonstrated a significant inverse correlation (OR = 0.509, p = 0.007). WBC count 
      had an R2 of 0.237, indicating that this marker could account for up to 23.7% of 
      a variation in Fib-4. Fib-4 and FFA had positive correlation which did not 
      achieve statistically significant prediction (OR=7.122, p=0.062). Additionally, a 
      significant prediction of HbA1c (OR=1.536, p=0.016) and haemoglobin (OR=1.071, 
      p=0.020) for FLI was revealed. CONCLUSION: HbA1c and other haematological and 
      metabolic parameters, such as haemoglobin and WBC, may be another non-invasive 
      tool for determining whether non-obese NAFLD patients with t2DM are at risk of 
      developing liver steatosis and fibrosis.
CI  - (c)2022 Acta Endocrinologica (Buc).
FAU - Mitrovic, B
AU  - Mitrovic B
AD  - Zemun Clinical Hospital, Faculty of Medicine, University of Belgrade - Department 
      of Endocrinology and Diabetes, Belgrade, Serbia.
FAU - Gluvic, Z
AU  - Gluvic Z
AD  - Zemun Clinical Hospital, Faculty of Medicine, University of Belgrade - Department 
      of Endocrinology and Diabetes, Belgrade, Serbia.
FAU - Klisic, A
AU  - Klisic A
AD  - Primary Health Care Center, University of Montenegro, Faculty of Medicine, 
      Podgorica, Montenegro.
FAU - Obradovic, M
AU  - Obradovic M
AD  - VINCA Institute of Nuclear Sciences - National Institute of the Republic of 
      Serbia, University of Belgrade - Department of Radiobiology and Molecular 
      Genetics.
FAU - Macut, D
AU  - Macut D
AD  - University of Belgrade Faculty of Medicine - Clinic of Endocrinology, Diabetes 
      and Diseases of Metabolism.
FAU - Tomasevic, R
AU  - Tomasevic R
AD  - Zemun Clinical Hospital, Faculty of Medicine, University of Belgrade - Department 
      of Gastroenterology and Hepatology Belgrade, Serbia.
FAU - Isenovic, E R
AU  - Isenovic ER
AD  - VINCA Institute of Nuclear Sciences - National Institute of the Republic of 
      Serbia, University of Belgrade - Department of Radiobiology and Molecular 
      Genetics.
LA  - eng
PT  - Journal Article
PL  - Romania
TA  - Acta Endocrinol (Buchar)
JT  - Acta endocrinologica (Bucharest, Romania : 2005)
JID - 101269720
PMC - PMC10162827
OTO - NOTNLM
OT  - FLI score
OT  - Fib-4
OT  - NAFLD
OT  - liver biopsy
OT  - liver fibrosis
OT  - t2DM
COIS- The authors declare that they have no conflict of interest.
EDAT- 2023/05/08 06:42
MHDA- 2023/05/08 06:43
PMCR- 2023/04/01
CRDT- 2023/05/08 04:09
PHST- 2023/05/08 06:43 [medline]
PHST- 2023/05/08 06:42 [pubmed]
PHST- 2023/05/08 04:09 [entrez]
PHST- 2023/04/01 00:00 [pmc-release]
AID - aeb-18-480 [pii]
AID - 10.4183/aeb.2022.480 [doi]
PST - ppublish
SO  - Acta Endocrinol (Buchar). 2022 Oct-Dec;18(4):480-487. doi: 10.4183/aeb.2022.480.